Forest Hills Lab Announces Additions to Cos-Med Division Leadership Team

Ella Fong joins as Commercial Director, Ik-Hwan Cho as CEO of NewMedic subsidiary

HONG-KONG, May 10, 2022 /EINPresswire.com/ — Forest Hills Laboratory (FHL) is an innovative regenerative medicine company that seeks to improve the quality of life in our rapidly aging society. The Cos-Med division of FHL, which develops and markets a full line of aesthetic products globally, today announced the appointment of Ella Fong to its leadership team as Chief Commercial Officer. In parallel, Newmedic, the Korean HA filler manufacturing and skin care products R&D subsidiary of FHL, announces the appointment of Ik-Hwan Cho as General Manager. These additions of talented and experienced professionals underscore FHL’s commitment to attracting world-class talent to drive the future growth of the Cos-Med division.

“We are very happy to have Ella and Mr. Cho join our team. They both bring deep expertise and extensive backgrounds to their respective roles. We are confident that they will help FHL develop innovative products and bring them to customers in need,” said Alex Yang, Chairman and CEO of FHL.

Ella Fong is a highly accomplished business executive with over 20 years of experience leading business efforts within multinational corporations. She previously worked at Galderma as the Hong Kong and Macao business unit manager for aesthetics and prescription drugs. There, she had full responsibility for the P&L and led all business strategies. Prior to that, she worked at Abbot Laboratories as a sales manager in Hong Kong and Macao and a cross-border e-commerce manager to China. At Abbott, she was part of the Hong Kong leadership team and led the Science-based Nutrition & Healthcare business. Previously, Fong also held commercial leadership positions in a variety of other industries, including companies: FrieslandCampina, Wyeth (acquired by Pfizer in 2009 and Nestlé in 2012) and Swire Coca-Cola.

“I am excited to join Forest Hills Lab at a time when we have the opportunity to further shape the business organization and strategies for our innovative product portfolio,” said Fong. “I look forward to working with the management team to effectively bring our growing product portfolio to our customers.”

Ik-Hwan Cho is an industry veteran with over 30 years of experience in the pharmaceutical and cosmeceutical industry. Previously, he served as Executive Director at Hugel, where he managed research and development, production and external operations for Korea’s leading facial injectables company. Previously, he also held a similar position at GC Pharma, a Korean biopharmaceutical company. Cho also spent 2 years at the Korean National Institute of Health working on pharmaceutical and clinical research and development, and served as a member of KFDA’s Biopharmaceutical Industry Cooperation Committee and Operating Chairman of the Sub – Overseas Biopharmaceutical Trade Committee of KFDA.

“Joining New Medic and Forest Hills Lab now is an incredible opportunity to help our innovative, high-quality products reach a broad, global customer base. I look forward to working with our global team,” Cho said.

About Forest Hills Lab
Forest Hills Lab is an innovative regenerative medicine company that seeks to improve the quality of life in our rapidly aging society. FHL is made up of two divisions: Neuro-Med and Cos-Med. The Neuro-Med division of FHL is a therapeutic drug development platform focused on high unmet need neurodegenerative diseases. The Cos-Med division of FHL develops and markets a full line of aesthetic products worldwide.

The main shareholder of Forest Hills Lab is Mstone Partners, a biotech entrepreneurial incubator in the form of a holding company that owns and manages a portfolio of drug development companies. Mstone focuses on pediatric and repurposed medicines, rare and neurodegenerative diseases and innovative technologies for targeted indications. Since its inception in 2016, Mstone has invested in two US companies and one in Hong Kong, which are now in advanced clinical stages with the US FDA. Mstone has also created a number of portfolio companies under the Curestone platform, which manages a portfolio of drug development companies in a centralized hub-and-spoke model.

For more information, please visit https://foresthillslab.com/.

Andrew O
Forest Hills Laboratory
[email protected]